BCL2 and diffuse large B-cell lymphoma: Results from a randomized phase II/III trial of venetoclax plus immunochemotherapy (R-CHOP or DA-EPOCH-R) vs immunochemotherapy alone in patients newly diagnosed DLBCL/high-grade B-NHL with translocation of BCL2 and MYC or dual expression of BCL-2 and MYC proteins are eagerly awaited.